Gene therapy for prostate cancer

Current status and future prospects

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prostate is an ideal target organ for gene therapy as a translational research. It has some advantages as follows: prostate is not a life keeping organ, can be approached easily by ultrasound as a routine clinical practice and PSA is a sensitive and useful tumor marker for the evaluation of clinical response. Intraprostatic therapeutic gene transduction (in situ gene therapy) is one of the potent therapeutic options for prostate cancer gene therapy aiming at antimetastatic benefits through the generation of immune cell-mediated cytotoxic activities that affect not only the primary tumor but also metastatic lesion. In this chapter, current outcome and future prospect of prostate cancer gene therapy are discussed.

Original languageEnglish
Title of host publicationHormone Therapy and Castration Resistance of Prostate Cancer
PublisherSpringer Singapore
Pages397-406
Number of pages10
ISBN (Electronic)9789811070136
ISBN (Print)9789811070129
DOIs
Publication statusPublished - May 11 2018

Fingerprint

Genetic Therapy
Prostatic Neoplasms
Neoplasm Genes
Prostate
Translational Medical Research
Tumor Biomarkers
Therapeutics
Genes
Neoplasms

Keywords

  • Anti-tumor immunity
  • Apoptosis
  • Cancer vaccine
  • Gene therapy
  • Prostate cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nasu, Y., & Watanabe, M. (2018). Gene therapy for prostate cancer: Current status and future prospects. In Hormone Therapy and Castration Resistance of Prostate Cancer (pp. 397-406). Springer Singapore. https://doi.org/10.1007/978-981-10-7013-6_40

Gene therapy for prostate cancer : Current status and future prospects. / Nasu, Yasutomo; Watanabe, Masami.

Hormone Therapy and Castration Resistance of Prostate Cancer. Springer Singapore, 2018. p. 397-406.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nasu, Y & Watanabe, M 2018, Gene therapy for prostate cancer: Current status and future prospects. in Hormone Therapy and Castration Resistance of Prostate Cancer. Springer Singapore, pp. 397-406. https://doi.org/10.1007/978-981-10-7013-6_40
Nasu Y, Watanabe M. Gene therapy for prostate cancer: Current status and future prospects. In Hormone Therapy and Castration Resistance of Prostate Cancer. Springer Singapore. 2018. p. 397-406 https://doi.org/10.1007/978-981-10-7013-6_40
Nasu, Yasutomo ; Watanabe, Masami. / Gene therapy for prostate cancer : Current status and future prospects. Hormone Therapy and Castration Resistance of Prostate Cancer. Springer Singapore, 2018. pp. 397-406
@inbook{85d4ab11da5c49a194dde9488d144880,
title = "Gene therapy for prostate cancer: Current status and future prospects",
abstract = "Prostate is an ideal target organ for gene therapy as a translational research. It has some advantages as follows: prostate is not a life keeping organ, can be approached easily by ultrasound as a routine clinical practice and PSA is a sensitive and useful tumor marker for the evaluation of clinical response. Intraprostatic therapeutic gene transduction (in situ gene therapy) is one of the potent therapeutic options for prostate cancer gene therapy aiming at antimetastatic benefits through the generation of immune cell-mediated cytotoxic activities that affect not only the primary tumor but also metastatic lesion. In this chapter, current outcome and future prospect of prostate cancer gene therapy are discussed.",
keywords = "Anti-tumor immunity, Apoptosis, Cancer vaccine, Gene therapy, Prostate cancer",
author = "Yasutomo Nasu and Masami Watanabe",
year = "2018",
month = "5",
day = "11",
doi = "10.1007/978-981-10-7013-6_40",
language = "English",
isbn = "9789811070129",
pages = "397--406",
booktitle = "Hormone Therapy and Castration Resistance of Prostate Cancer",
publisher = "Springer Singapore",

}

TY - CHAP

T1 - Gene therapy for prostate cancer

T2 - Current status and future prospects

AU - Nasu, Yasutomo

AU - Watanabe, Masami

PY - 2018/5/11

Y1 - 2018/5/11

N2 - Prostate is an ideal target organ for gene therapy as a translational research. It has some advantages as follows: prostate is not a life keeping organ, can be approached easily by ultrasound as a routine clinical practice and PSA is a sensitive and useful tumor marker for the evaluation of clinical response. Intraprostatic therapeutic gene transduction (in situ gene therapy) is one of the potent therapeutic options for prostate cancer gene therapy aiming at antimetastatic benefits through the generation of immune cell-mediated cytotoxic activities that affect not only the primary tumor but also metastatic lesion. In this chapter, current outcome and future prospect of prostate cancer gene therapy are discussed.

AB - Prostate is an ideal target organ for gene therapy as a translational research. It has some advantages as follows: prostate is not a life keeping organ, can be approached easily by ultrasound as a routine clinical practice and PSA is a sensitive and useful tumor marker for the evaluation of clinical response. Intraprostatic therapeutic gene transduction (in situ gene therapy) is one of the potent therapeutic options for prostate cancer gene therapy aiming at antimetastatic benefits through the generation of immune cell-mediated cytotoxic activities that affect not only the primary tumor but also metastatic lesion. In this chapter, current outcome and future prospect of prostate cancer gene therapy are discussed.

KW - Anti-tumor immunity

KW - Apoptosis

KW - Cancer vaccine

KW - Gene therapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85053171652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053171652&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-7013-6_40

DO - 10.1007/978-981-10-7013-6_40

M3 - Chapter

SN - 9789811070129

SP - 397

EP - 406

BT - Hormone Therapy and Castration Resistance of Prostate Cancer

PB - Springer Singapore

ER -